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Inhibition of MCP-1 Reduce Angiogenesis and Tumor
Growth in a Human Melanoma Xenograft
Silvina Gazzaniga1, Alicia I Bravo2, Angelo Guglielmotti3, Nico van Rooijen4, Fabricio Maschi5,
Annunciata Vecchi6, Alberto Mantovani6, Jose´ Mordoh7 and Rosa Wainstok1
Chemokines such as monocyte chemoattractant protein (MCP)-1 are key agonists that attract macrophages to
tumors. In melanoma, it has been previously shown that variable levels of MCP-1/CCL2 appear to correlate with
infiltrating macrophages and tumor fate, with low to intermediate levels of the chemokine contributing to
melanoma development. To work under such conditions, a poorly tumorigenic human melanoma cell line was
transfected with an expression vector encoding MCP-1. We found that M2 macrophages are associated to MCP-
1þ tumors, triggering a profuse vascular network. To target the protumoral macrophages recruitment and
reverting tumor growth promotion, clodronate-laden liposomes (Clod-Lip) or bindarit were administered to
melanoma-bearing mice. Macrophage depletion after Clod-Lip treatment induced development of smaller
tumors than in untreated mice. Immunohistochemical analysis with an anti-CD31 antibody revealed scarce
vascular structures mainly characterized by narrow vascular lights. Pharmacological inhibition of MCP-1 with
bindarit also reduced tumor growth and macrophage recruitment, rendering necrotic tumor masses. We
suggest that bindarit or Clod-Lip abrogates protumoral-associated macrophages in human melanoma
xenografts and could be considered as complementary approaches to antiangiogenic therapy.
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INTRODUCTION
Monocyte chemoattractant protein-1 (MCP-1/CCL2) plays a
critical role in the recruitment and activation of macrophages
during acute inflammation (Mantovani et al., 2004). It has
also been shown that, in melanoma cell lines transduced with
MCP-1 gene that secrete different levels of the chemokine,
MCP-1 action is biphasic. Whereas high levels promote
tumor rejection, low or intermediate levels support tumor
growth (Nesbit et al., 2001). Macrophages are important
components of the innate immunity against tumors, which
are attracted by locally secreted chemokines (Brigati et al.,
2002; Coussens and Werb, 2002). Owing to their plasticity,
the macrophage functional program appears to be defined by
the presence of growth factors in the tumor microenviron-
ment as well as by intercellular interactions (Mills et al.,
2000). Consequently, there is a duality in the functional value
of tumor-associated macrophages. When totally polarized to
M1, macrophages are involved in type I reactions and may
kill tumor cells. On the other hand, M2 macrophages tune up
inflammation, produce angiogenic factors and metallopro-
teases, induce a certain degree of immunosuppression, and
stimulate tumor growth (Mills, 2001; Brigati et al., 2002;
Mantovani et al., 2002).
Human melanoma is a disease with extremely variable
growth rates in vivo and on the basis of the above-mentioned
results it seemed worth investigating (a) the type of
macrophages that arrive to the tumor, (b) how to modulate
macrophage infiltration, and (c) how the expression level of
MCP-1 could be inhibited to diminish tumor growth rate.
To approach these issues, we have used the human
melanoma cell line IIB-MEL-J as a model (Gazzaniga et al.,
2001), which has no production of MCP-1 (Gazzaniga et al.,
unpublished results) and which grows slowly when
xenografted into nude mice. We have transfected this cell
line with an MCP-1-expression vector and obtained
an intermediate MCP-1 producer, which grows faster
in vivo. Bindarit (2-methyl-2-((1-(phenylmethyl)-1H-indazol-
3yl) methoxy) propanoic acid) inhibits MCP-1 production
in vitro and in vivo (Guglielmotti et al., 2002) and the anti-
MCP-1 action results in beneficial effects in models of some
diseases (Guglielmotti et al., 2002; Bathia et al., 2005). This
suggests that the blockage of this chemokine production or its
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action is a major target for pharmacological intervention in
different human diseases, raising the possibility of therapeutic
strategies to target specific macrophages attracted by the
chemokine MCP-1 at the tumor site. Clodronate (dichlor-
omethylene–biphosphonate) encapsulated into liposomes can
be delivered so that it is captured by phagocytic cells. Killing
of these cells is the result of intracellular accumulation and
irreversible metabolic damage that causes apoptotic death
(van Rooijen et al., 1996). Here, we provide direct evidence
that M2 macrophages are present locally in MCP-1-produ-
cing melanoma, promoting vascularization and tumor
growth. Most importantly, targeting macrophages or MCP-1
production through two different pharmacological ap-
proaches renders tumors less aggressive with a clear
reduction of intratumoral vascular network.
RESULTS
Transfection of the human IIB-MEL-J melanoma cell line
To establish a stable model to evaluate the contribution of
MCP-1 to tumor growth, we have chosen the melanoma cell
line IIB-MEL-J, which does not produce the chemokine. The
level of MCP-1 released to the cell culture supernatant was
less than 12 pg/ml/106 cells/48 hours. After lipofection with
the pLXSN-MCP-1 plasmid, we were able to select a stable
subline, IIB-MEL-J-MCP-1, which expressed MCP-1 mRNA
and released 940 pg/ml/106 cells/48 hours. Mock-transfected
cells (with the empty vector pLXSN) retained the character-
istics of the parental line in terms of MCP-1 production
(Figure 1a). Every experiment conducted thereafter, included
parental and mock-transfected IIB-MEL-J as independent
groups and will be referred as control lines along the work.
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Figure 1. Characterization of IIB-MEL-MCP-1-transfected cell line. (a) Expression of MCP-1 mRNA by melanoma cell lines. The amplified specific fragment of
235 bp is present in the permanently transfected IIB-MEL-J-MCP-1. Analysis of b-actin served as internal control. (b) Chemoattractant capacity of serum-free
conditioned media from the different melanoma lines assayed in a chemotaxis chamber. The number of migrated macrophages after 2 hours was counted in five
high-power fields. Determinations were done by triplicate (***Po0.0001, Student’s t-test). (c) Tumor dimensions were measured with a caliper and for
microscopic tumor masses, dimensions were taken on hematoxylin–eosin sections with reticulated ocular in 5–10 different tumor samples. Triangle: IIB-MEL-J-
MCP-1, square: IIB-MEL-J and mock-transfected lines. (*P¼ 0.015, Wilcoxon’s rank-sum test). (d) In vitro growth rate: 50,000 cells of each line were plated onto
96-well dishes and cultured in complete melanoma medium. Cells were quantified at different time points with 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide. Full square: parental line; full triangle: IIB-MEL-J-MCP-1; empty square: mock-transfected line. Determinations were done by
quadruplicates. CCR2 expression in (e) control, (f) IIB-MEL-J-MCP-1, and (g) 1G11 lines. Gray histogram corresponds to isotype control and white histogram to
the reactivity to CCR2 chemokine receptor with rabbit mAb. Percentages depicted above the marker line indicate the fraction of CCR2-positive cells.
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To test whether the chemokine released by IIB-MEL-J-
MCP-1 was functional, serum-free culture supernatants were
seeded in the lower compartment of a chemotaxis chamber.
Monocyte/macrophage migration was only induced by IIB-
MEL-J-MCP-1-conditioned medium (Figure 1b) and blocked
when supernatants were preincubated with a specific anti-
body against MCP-1 (data not shown). Control lines-condi-
tioned media were not chemoattractant for monocytes/
macrophages (Figure 1b). When injected subcutaneously
into nude mice, IIB-MEL-J-MCP-1 developed larger tumors
than those of control cell lines: tumors attained statistical
significant differences (P¼0.015) after 11 days of inoculation
up to the end of the observation period (day 20) (Figure 1c).
This increased growth velocity could not be attributed to an
alteration of cell properties after transfection. In vitro growth
kinetics of IIB-MEL-J-MCP-1 and control cell lines were
similar (Figure 1d). In addition, the main receptor for MCP-1,
CCR2, was absent (Figure 1e and f) discarding a putative
autocrine role in tumor growth rate.
Inflammatory infiltration and angiogenesis
Tumor samples were obtained at different intervals to
examine the occurrence and localization of inflammatory
infiltrate. Recruitment of macrophage-like cells within and
around tumors was significantly higher (P¼ 0.01) in MCP-1-
transfected tumors than in control tumors from early stages of
tumor establishment until the end of the observation period
(Figure 2a and b and Table 1). Eleven days after IIB-MEL-J-
MCP-1 injection, the macrophage-like cells recruitment
persisted and was accompanied by fibroblasts and edema,
alterations that were absent in control tumors (data not
shown). There was scarce presence of peritumoral lympho-
cyte-like cells, although polymorphonuclear neutrophils
increased peritumorally 4 days post-IIB-MEL-J-MCP-1 cells
implantation (Table 1). The above-described inflammatory
infiltrate was absent in control tumors.
To analyze the phenotypic identity of the mononuclear
infiltrates and the degree of vascularization, consecutive tumor
sections were stained with primary antibodies to detect CD31,
F4/80, and CX3CR1 expression. Four days after IIB-MEL-J-
MCP-1 injection, a peripheral border of incipient vessels
appeared as well as isolated CD31þ cell clusters (Figure 2c).
Concerning F4/80, a striking positivity was found around
tumor mass and also among neoplastic cells (Figure 2e). For
CX3CR1, a fainter staining was present peri- and intratumorally
partially overlapping with F4/80 areas (data not shown).
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Figure 2. Inflammatory infiltration and angiogenesis. (a) Mononuclear cells are mainly present among IIB-MEL-J-MCP-1 cells (11 days growing tumors)
(b) Control tumors present no mononuclear infiltration. Bar¼ 10mm. Immunohistochemical analysis identifying (c and d) CD31þ and (e and f) F4/80þ cells in
11-day (c and e) IIB-MEL-J-MCP-1 (d and f) and control melanoma. Bar¼ 125mm.
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When 11-day IIB-MEL-J-MCP-1 tumors were analyzed, a
strong positivity for CD31 was detected and revealed a
massive branched intratumoral vascular network. This
important vascularization was completely absent in control
tumors where MCP-1 was not produced. Surprisingly, no
differences were found peritumorally in terms of CD31þ
vessels and cell clusters (Table 2). The intratumoral differ-
ences between IIB-MEL-J-MCP-1 and control tumors were
also extensive to F4/80 and CX3CR1 macrophages infiltration.
Surrounding macrophages were present in control tumors,
although recruitment was increased in those generated from
cells transfected for MCP-1 expression (Table 2). Eleven days
post-injection of neoplastic cells, tumors showed a well-
established angiogenic network. Consequently, we focused
on days 4 and 11 as a prevascularized and vascularized time
points in tumor development, respectively.
The immunohistochemical analysis revealed the presence
of cells identified as macrophages but this marker positivity
does not reveal their functional significance in tumor tissues.
For this purpose, two characteristic enzymes were deter-
mined. Type I macrophages (M1 macrophages), which
synthesize inducible nitric oxide (iNOS) but not arginase,
were proposed to be tumoricidal macrophages, whereas M2
macrophages, which synthesize arginase but not iNOS,
would be protumoral (Sironi et al., 1999; Schmeisser et al.,
2001; Koide et al., 2004).
To determine which type of infiltrating macrophages are
present at IIB-MEL-J-MCP-1 melanomas, extracts from 4-day
tumor sites were prepared to test in vitro arginase and iNOS
activities (Figure 3). Macrophages infiltrating IIB-MEL-J-MCP-
1 tumors presented a significant reduction of nitric oxide
(P¼0.005) and arginase tended to be augmented with
respect to control tumor sites, although this difference does
not reach statistical signification (Figure 3).
Depletion of macrophages with Clod-Lip
To determine how critical macrophages were to the
increased growth ability of MCP-1-transfected melanoma,
mice were depleted of phagocytic cells by the administration
of Clod-Lip as described. Intravenous and local injections of
Clod-Lip were intended to eliminate early recruitment of
macrophages, which could be attracted by the chemokine
released once transfected tumor cells were injected. Under
this condition, IIB-MEL-J-MCP-1 tumors grown in mice
treated with Clod-Lip showed a reduction superior to 70%
(P¼0.0003, Student’s t-test) in tumor bulk (Figure 4a) as
compared with tumor growth in undepleted mice. Mice
survival also increased with macrophage depletion (data not
shown). Growth rates for parental or mock-transfected tumors
remained unchanged with treatment (Figure 4b).
To verify the intensity of macrophage depletion obtained
by Clod-Lip, tumor sites from Clod-Lip-treated and untreated
Table 1. Quantitative analysis of peritumoral and intratumoral infiltrating cells1
Peritumoral
Macrophage-like cells Lymphocyte-like cells Polymorphonuclear cells
Days Control MCP-1+ Control MCP-1+ Control MCP-1+
4 2 (0–11) 4** (0–26) 0 (0–4) 0 (0–3) 0 (0–3) 2** (0–22)
11 1 (0–4) 4** (0–14) 0 0 0 (0–2) 0 (0–2)
20 2 (0–20) 33** (0–70) 0 (0–2) 0 (0–2) 0 (0–3) 0 (0–6)
Intratumoral
4 2 (0–10) 5** (0–33) 0 (0–2) 0 (0–2) 0 (0–3) 0 (0–8)
11 2 (0–6) 3* (0–9) 0 0 0 (0–1) 0
20 0 (0–2) 8** (0–30) 0 (0–1) 0 (0–1) 0 (0–1) 0
MCP, monocyte chemoattractant protein.
1Counts were performed in 10 fields of original magnification 1000. Values correspond to medians and ranks. *P=0.05 and **P=0.01 (Wilcoxon’s rank
test).
Table 2. Immunoreactive cells in 11-day tumors1
Vessels CD31+ clusters F4/80+ cells CX3CR1+ cells
IIB-MEL-J-MCP-1 Intratumorally +++ +++ 140 35
Peritumorally +++ +++ 242 37
Control Intratumorally   2 0
Peritumorally +++ +++ 174 42
1Total cell counts performed at 10 high-power fields and vascularization at original magnification 200 fields. Vascular structures and cell clusters were
ranked as: + (o10 elements); ++ (10–20 elements), and +++ (420 elements).
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mice could not be stained with F4/80 owing to intense
necrosis and chromogen deposition. Instead, a fluorochrome-
labelled CD11b mAb was used. Abundant positive macro-
phages were easily identified at the tumor site in 4-day IIB-
MEL-J-MCP-1 but were scarcely present in Clod-Lip-treated
tumor (Figure 4c). To investigate whether macrophage
depletion had an impact on vascularization, tumor biopsies
were analyzed for CD31 expression (Figure 4d). A deep
reduction in angiogenesis was observed with respect to
nontreated tumors. Tumor vessel circumferences were
significantly reduced (64.5775.86 vs 128.1279.13 mm;
P¼0.003) (Figure 4d inset and 4e). In contrast, control
tumors did not present variations of vessels morphology with
treatment (not shown). To discard a direct cytostatic/cytotoxic
effect of Clod-Lip on melanoma cells or endothelium, cells
were incubated in vitro with Clod-Lip or phosphate-buffered-
saline-Lip. No significant effect on viability was recorded
neither on different tumor nor endothelial cells (ECs) by Clod-
Lip exposure during 30 (Figure 4f) or 72 hours (not shown),
whereas this treatment was cytotoxic for macrophages and
polymorphonuclear cells (P¼0.05, Figure 4f).
Bindarit treatment
Even when an important reduction in tumor burden was
obtained with Clod-Lip as a consequence of disrupting
macrophages recruitment to tumor site, there was an
incipient angiogenesis characterized by smaller vessels. This
precarious microvascular development could be because of
some angiogenic potency of MCP-1 itself. To address this
issue, mice were injected intraperitoneally with bindarit at a
dose of 100 mg/kg twice a day, beginning the same day that
tumor cells were subcutaneously inoculated. Bindarit treat-
ment was maintained until the animals were killed to sample
tumor tissues for histology. The analysis revealed a reduction
in IIB-MEL-J-MCP-1 tumor volume with respect to control
tumors, both at days 4 and 11 post-treatment (P¼0.05,
Wilcoxon’s rank test) (Figure 5a). Exclusively, tumors expres-
sing MCP-1 were almost completely necrotic when
examined at days 4 and 11 after treatment (P¼ 0.0022 and
0.01) (Figure 5b and c). The combination of bindarit and
Clod-Lip did not improve this result (data not shown).
Macrophages recruitment was abolished by bindarit (Figure
5c). Control lines were not affected by the drug (data not
shown). Bindarit, even at the maximal concentration, did
not exhibit a direct in vitro cytotoxic effect on melanoma
(Figure 6a and b) or ECs (Figure 6c), although it inhibited
MCP-1 expression (Figure 6d).
Effect of MCP-1 on ECs
The results obtained above suggest that MCP-1 plays a role to
vascularize IIB-MEL-J-MCP-1 tumors, as there is still a
precarious neovessel development even after reducing
macrophages with Clod-Lip. To assess whether MCP-1 could
induce vascularization, murine microvascular ECs were
incubated with different concentrations of recombinant
MCP-1. No induction of proliferation was found (Figure 7a),
discarding its contribution as a mitogenic agent on ECs.
However, when the same microvascular ECs were incubated
in matrigel, tubular structures were induced to organize in the
presence of recombinant chemokine (100 ng/ml) (Figure 7b)
or conditioned supernatants from IIB-MEL-J-MCP-1 (data not
shown). A specific antibody against MCP-1 aborted ECs
organization in tubules and only precarious buds were
observed emerging from cell clusters (Figure 7c). Tubule
structures were not altered by the addition of an isotype
control antibody and no structures were formed when
microvascular ECs were grown alone or after adding
conditioned supernatants from control lines (not shown).
DISCUSSION
MCP-1 released by cancer cells recruits macrophages into
tumor tissue (Desbaillets et al., 1994; Negus et al., 1997;
Valkovic et al., 1998). The role of this chemokine in tumor
progression and metastasis is a subject of interest in prognosis
as well as in the development of possible antitumor strategies
(Varney et al, 2002; Ohta et al., 2003; Koide et al., 2004;
Colombo and Mantovani, 2005; Kuroda et al., 2005).
Macrophages respond to the released chemotactic envir-
onmental signals with diverse functional programs (Mills
et al., 2000) and this inflammatory scenario has been
associated with neoplasia (Coussens and Werb, 2002;
Balkwill et al., 2005).
In this study, we performed transfection of the human
melanoma cell line IIB-MEL-J (negative for MCP-1 produc-
tion) with the purpose to have a MCP-1 intermediate-
producer melanoma model to distinctively analyze the
contribution of this chemokine in the profile of recruited
macrophages and the effect on tumor growth. The compari-
son of different melanoma cell lines with spontaneous
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capacity to produce MCP-1 could be confusing as there are
several angiogenic and antiangiogenic factors that could not
be kept as constants. Most importantly, in this work, we
focused on the effect of Clod-Lip and bindarit as putative
agents to abolish protumoral effect of macrophages.
At the light of our results, the significant presence of
intratumoral macrophages during the early stages of tumor
progression and their persistence during evolution seem to be
responsible for tumor growth promotion. We found that
tumor dimensions of IIB-MEL-J-MCP-1 tumors enhanced 3.5-
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Clod-Lip mice. Tumor sections from IIB-MEL-J-MCP-1 tumor grown in Clod-Lip-treated and untreated mice were immunostained for CD31 detection.
(Bar¼100 mm, insets bars: 100 mm). (e) Quantification of tumor vessels areas was performed on immunostained sections with Kontron Electronics software
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independent experiments were performed. (*Po0.04, Student’s t-test).
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and 18-fold after 4 and 11 days, respectively. The absence of
CCR2 expression in melanoma cells discards the possibility
of autocrine effect of the chemokine released by IIB-MEL-J-
MCP-1 cells.
Apart from F4/80-positive cells recruitment, an important
afflux of CD31þ cells was present nearby the incipient
tumors. We also found a strong reduction in the levels of
nitric oxide in IIB-MEL-J-MCP-1 tumors and an augmented
arginase activity, outlining the presence of M2 macrophages
recruited to the tumor. We propose that IIB-MEL-J-MCP-1
tumors grew highly vascularized owing to the presence of M2
macrophages, which could be contributing with an important
source of angiogenic factors (Schmeisser et al., 2001;
Coussens and Werb, 2002; Varney et al., 2005) or favoring
vasculogenesis (Anghelina et al., 2004; Anghelina et al.,
2006).
The protumoral effect of infiltrating macrophages in IIB-
MEL-J-MCP-1 was confirmed by Clod-Lip treatment results.
We observed a substantial reduction in tumor growth MCP-1-
transfected melanoma xenografts after macrophage deple-
tion. We did not find direct cytotoxicity on melanoma cells
or endothelial employing Clod-Lip, which implies that the
drug is captured selectively by phagocytic cell and there
is no uptake by the other two cell types in the tumor.
Clodronate is a non-nitrogen biphosphonate and when
encapsulated, it is metabolized intracellularly to a b–g
methylene analog of adenosine triphosphate, that is cytotoxic
to macrophages in vitro (van Rooijen et al., 1996; Lehenkari
et al., 2002). Without encapsulation, clodronate exerts no
inhibition in cell proliferation either in vitro or in vivo in
solid tumors (cutaneous and uveal melanomas) (Knight et al.,
2005).
Instead, nitrogen-containing biphosphonates had a direct
effect through induction of apoptosis on tumor cells
(Yamagishi et al., 2004; Knight et al., 2005).
Thus, the choice of Clod-Lip allowed dividing clearly the
role of macrophages respect to a direct influence on tumor
cells.
Even when there was a significant tumor reduction in
IIB-MEL-J-MCP-1 with Clod-Lip treatment, we found that
there was still perfusion through a poor vessel network
with very small calipers. As it has been previously shown,
the origin of this modest vascular formation could be
owing to EC migration and/or sprouting from local residing
ECs or recruitment of circulating endothelial progenitors
(Asahara et al., 1997; Skovseth et al., 2002; Spring et al.,
2005).
By using bindarit, a molecule that has been shown to
inhibit MCP-1 production both in vitro and in vivo (Sironi
et al., 1999; Guglielmotti et al., 2002; Bathia et al., 2005), we
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(c) Representative images of 11-day IIB-MEL-MCP-1 tumors. A tumor from vehicle-treated animals appeared surrounded by macrophage infiltration
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could abolish such vascularization, rendering tumors almost
completely necrotic. When necrosis was not complete, the
scarce viable remaining tumor cells were exclusively located
at the periphery of the tumor mass. As no direct cytotoxicity
appeared from in vitro assays, the effect of bindarit treatment
was assumed to happen because of the lack of attracting
signals for the macrophages.
It was observed, in a macrovascular endothelium model as
human umbilical vein endothelial cells (Salcedo et al., 2000)
and in this paper using microvascular ECs (Figure 7), that
MCP-1 induces ECs to arrange spatially forming tube-like
structures without evident proliferation (Figure 7). This
behavior is MCP-1-specific provided that the tubularization
process was blocked by a specific antibody to the chemokine
but not by the appropriate isotype control. Consequently,
according to our results, MCP-1 would be predisposing ECs to
an ‘‘angiogenic state’’ but the signals to proliferate would
come with the presence other angiogenic component/s of
tumor microenvironment. Vascular Endothelial Growth
Factor (VEGF) could be one of these candidates, as it is
expressed by IIB-MEL-J melanoma cells and transfectants
(data not shown). The monocyte is an example of a non-EC
type that is positive for VEGF R1, active on monocyte
chemotaxis (Mantovani et al., 2004). According to these
evidences, it is tempting to speculate that, when only VEGF is
present, melanoma vascularizes poorly, as it occurs with IIB-
MEL-J tumors. Contrarily, with MCP-1 adjuvancy, more
macrophages reach the tumor site to trigger a profuse
vascular network, permitting a more aggressive tumor
development.
This role of MCP-1 in orchestrating recruitment of M2
macrophages but, above all, tumor vascularization by multi-
ple ways drives the attention to future therapies using drugs
like Clod-Lip or bindarit, which could block or reduce the
inflammatory effects of this chemokine.
MATERIALS AND METHODS
Melanoma cell lines
The human melanoma cell lines IIB-MEL-J and transfectants, IIB-
MEL-IAN and IIB-MEL-LES were maintained in DMEM: Ham F12
medium (1:1), supplemented with 10% fetal bovine serum (FBS),
20 nM sodium selenite, 100 mM ascorbic acid, 0.15 mg/ml sodium
pyruvate, 0.3 mg/ml galactose, 5 mg/ml insulin, and 2 mM glutamine
(melanoma medium) as previously reported (Gazzaniga et al., 2001).
Cells were regularly tested to be mycoplasma-free. Transfection was
performed with LipofectamineTM (Life Technologies, Gaithersburg,
MD) with the pLXSN vector bearing a 700-bp long fragment of
human MCP-1 cDNA or with the empty vector (mock transfection).
Cultures were then selected with 800mg/ml G418 (Life Technolo-
gies), cloned, and expanded as cell lines. For tumor generation,
1.5 106 cells were subcutaneously injected in athymic male NIH
(S)-nu mice (6–8 weeks old, obtained from the Faculty of Veterinary
Sciences Facility, University of La Plata, Buenos Aires). Animal
handling and care were conducted in conformity with national and
international policies.
MCP-1 and CCR2 determinations
Released MCP-1 was quantified with commercially available
antibodies for ELISA (BD Biosciences, NJ). Development was
performed by adding chromogen substrate ABTS (KirKegaard and
Perry, Gaithersburg, MD) and the plates were read at 405 nm in an
automatic ELISA reader (BIORAD Laboratories Inc, Hercules, CA).
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Figure 6. Evaluation of bindarit cytotoxicity in vitro. Viability of (a) IIB-MEL-
J-MCP-1 and control lines; (b) IIB-MEL-IAN and IIB-MEL-LES, and (c) EC lines
were evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide assay. Values correspond to the mean of quadruplicates. Two
independent experiments were performed. (d) Immunodot detection of MCP-
1 production in 48 hours-conditioned supernatants of the different melanoma
cell lines cultured in absence or presence of bindarit (500 mM). Human
recombinant MCP-1 (200 ng, Peprotech) was seeded as positive control and
culture media as negative control.
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MCP-1 mRNA was determined by reverse transcriptase–PCR as
described by Luciani et al. (1998) using extracted RNA from every
cell line as template and the following specific primers (forward 50-
CTCAGCCAGATGCAATCAATG-30 and reverse 50-GTTCAAGTCTTC
GGACTTTGG-30).
CCR2 determination was performed by FACS analysis on 1%
paraformaldehyde-fixed cells using rabbit anti-human CCR2 (Ab-
cam, Cambridge Science Park, Cambridge, UK) (1/25) and goat anti-
rabbit conjugated to FITC (Sigma Chemicals Co., St Louis, MO)
(1/140). Results were analyzed with WinMDi program. Markers
were set with an inclusion criteria of less than 5% of the isotype
control population. The percentage of positive cells were calculated
with the statistical function of WinMDi program.
Treatments
For macrophage depletion, a suspension of clodronate liposomes
containing about 6 mg clodronate per 1 ml suspension was
employed. Clodronate was a gift of Roche Diagnostics (GmbH,
Mannheim, Germany) and it was encapsulated in liposomes as
described earlier (van Rooijen and Sanders, 1994). Other reagents
for preparation of liposomes are: phosphatidylcholine (Lipoid,
GmBH, Germany) and cholesterol (Sigma Chemicals Co.,).
Clodronate liposomes (200 and 50ml) were administered intrave-
nously (by retroorbital puncture) and subcutaneously (to deplete
local draining areas) the day before tumor cells injection and
thereafter every 5–7 days. For in vitro assays, 9mg/well were
employed.
Bindarit (Angelini Farmaceutici, ACRAF SpA, Italy) was intraper-
itoneally administered twice daily at a dose of 100 mg/kg weight
(12.5 ml/kg body weight). The control group received vehicle (0.5%
methylcellulose). Mice were killed at day 4 or 11 and tumors were
fixed in 10% buffered formalin. Tumor sizes and necrosis were
measured with a microscope caliper. Experiments (either with Clod-
Lip treatment or bindarit) were repeated twice and 4–6 animals were
included in each group. For in vitro assays, the compound was
resuspended in melanoma culture medium supplemented with 5%
FBS, added to cell cultures at 70–80% confluency, and incubated for
48 hours. Cell viability was determined with 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide and culture supernatants
were evaluated for MCP-1 production.
Tissue processing
For every group, tumors were bisected: one half of each specimen
was fixed in 10% buffered formalin, embedded in paraffin, sectioned
at 4–7 mm, and stained with hematoxylin–eosin. The other half was
frozen and stored at 801C for immunohistochemistry. Briefly,
acetone-fixed tumor sections were blocked with 5% normal rabbit
serum and incubated with optimal dilutions of the primary
antibodies. Rat anti-mouse mAbs used were MEC 13.3 (BD
Biosciences, Pharmingen, San Diego, CA) for CD31 detection, F4/
80 (Serotec Ltd., Oxford UK) for macrophages and anti-CX3CR1
fractalkine receptor (BD Biosciences). The specific binding was
revealed using 1/100 goat anti-rat IgG (Sigma Chemicals Co.), 1/500
rat peroxidase–antiperoxidase complex (Accurate Chemicals, West-
bury, NY), and 0.05% 3,30-diaminobenzidine (Sigma Chemicals Co.)
plus 0.03% H2O2. Endogenous peroxidase activity was blocked with
0.3% H2O2. All reagents except primary antibodies were used as
controls to confirm specific antibody binding.
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Figure 7. Effect of MCP-1 on ECs. (a) Microvascular proliferation in response to variable concentrations of human recombinant MCP-1. Cells were grown on
gelatin-coated wells in the presence of 0.5% FBS and after 24 hours cell number was revealed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
(b) Microvascular ECs depicting tube formation in vitro after cultured for 4 days in the presence of matrigel plus 100 ng/ml of human MCP-1. (c) ECs aborted
tubularization when grown in matrigel plus 100 ng/ml of human MCP-1 plus MCP-1 antibody (1 mg/ml). Bar¼ 10mm.
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Quantitative evaluations
Tumor bulk in vivo was reported as volume, determined by
measurement of the smallest and largest dimensions of the tumors
with a caliper. For microscopic tumors, dimensions were measured
with a reticulated ocular on counterstained tissue samples by
hematoxylin and eosin. Volumes were calculated as (a b2)/2,
where a is the larger dimension and b is the smaller dimension.
Determination of vessels areas were performed with an image
analyzer (KS 300 Kontron Electronik) coupled to an Axioplan
microscope (Zeiss, Germany). Cells were counted in at least 10
fields/sample at original magnification  1000.
NO and arginase assay
NO released in the cultures was measured by Griess reaction as the
amount of NO3
 and NO2
 produced by using a nitrate/nitrite assay
kit (Cayman Chemical, Ann Arbor, MI). Arginase activity was
measured in cell lysates as described by Corraliza et al. (1994).
EC viability
Ten thousand murine 1G11 ECs (Dong et al., 1997) and REC-A4 ECs
(Gazzaniga et al., 2004) were plated on gelatin-coated wells, left
overnight for adherence in DMEM medium supplemented with 0.5%
FBS, 2 mM glutamine, 1% nonessential amino acids and 2 mM
sodium pyruvate. H5V (Garlanda et al., 1994) were grown in DMEM
medium supplemented with 2 mM glutamine and 0.5% FBS and
plated without coating. Subsequently, cells from every cell line were
incubated for 24 hours with different drugs (bindarit, Clod-Lip, or
vehicles). After incubation, living cells were revealed by incubation
with 1 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (Sigma Chemicals Co.) and absorbances read at 595 nm.
Determinations were done by sextuplicate.
Tube-like structures in matrigel
Fifty thousand ECs (1G11) were plated on coverslips together with
matrigel (BD) (1.5 mg/ml) diluted in rhMCP-1 (Peprotech, Rocky
Hill, NJ), melanoma cells-conditioned medium. A mAb against
MCP-1 antibody (BD) (1mg/ml) was used to block MCP-1. Plates
were monitored everyday and photographs were taken at day 4 after
fixation with 1% paraformaldehyde in phosphate-buffered solution.
Chemotaxis assay
Migration of cells was evaluated using 5-mm pore size filters (Neurop-
robe Inc, Gaithersburg, MD) placed in a Boyden chamber. Every
melanoma line was grown till 90% confluence, maintenance medium
was removed and left for 48 hours in melanoma medium 1% FBS.
These conditioned media were placed into the lower chamber of the
Boyden chamber. Murine macrophages obtained from peritoneal cavity
were resuspended in serum-free melanoma medium at a concentration
of 1.5 106 cells/ml and 40ml of cell suspension was placed onto the
upper chamber. A mAb against MCP-1 antibody (BD) (1mg/ml) was
used to ensure specific migration. After an incubation of 2 hours at 371C
in 5% CO2, the upper chamber was removed and the cells in the lower
face of the filter stained and counted in five fields (original
magnification  400). Determinations were done by triplicate.
Statistical analysis
In vitro data were analyzed by using Student’s t-test and in vivo
results with the nonparametric Wilcoxon’s rank sum test using
Statistix software version 8.0 (Analytical Software, Tallahassee, FL).
Pp0.05 was considered statistically significant.
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